Document:

staf-ex101_7.htm

 

Exhibit 10.1

 

AMENDMENT AGREEMENT

 

 

This AMENDMENT AGREEMENT, dated as of February __, 2019 (this “Amendment”), is entered into by and among Staffing 360 Georgia, LLC, a Georgia limited liability company (“Buyer”), Firstpro Inc., a Georgia corporation (“FPI”), Firstpro Georgia, LLC, a Georgia limited liability company (“FPL” and, together with FPI, “Sellers” and, each individually, a “Seller”), April F. Nagel, an individual (“Mrs. Nagel”), and Philip Nagel, an individual (“Mr. Nagel” and together with Mrs. Nagel, the “Principals”).

RECITALS

WHEREAS, Buyer, Sellers and Principals are parties to that certain Asset Purchase Agreement dated as of September 15, 2017 (the “APA”);

WHEREAS, Sellers and Buyer have agreed that Buyer will make a single lump sum payment of $1,125,000 (the “Final Payment”) in full and final satisfaction of any remaining amounts payable to the Sellers under Section 1.05 of the APA;

WHEREAS, in connection with the parties’ execution and delivery of the APA, the Buyer and FPI entered into a Trademark License Agreement, dated September 15, 2017 (the “TLA”);

WHEREAS, Buyer and FPI desire to amend the TLA to make the term of the license given thereunder perpetual; and

WHEREAS, Buyer, Sellers and Principals desire to amend the APA and TLA to, among other things, give effect to the foregoing.

AGREEMENT

NOW, THEREFORE, in consideration of the premises and mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

Capitalized Terms

.  Capitalized terms used herein and not defined herein shall have the meanings ascribed to such terms in the APA.

2.The Final Payment.  Within five (5) Business Days after the date of this Agreement, the Buyer shall make the Final Payment to the Sellers by wire transfer of immediately available funds to an account identified in writing by Sellers. The Final Payment shall be in full and final satisfaction of all amounts that remain payable to Sellers under Section 1.05 of the APA.  

Amendments to APA

.  Upon Buyer’s deliver of the Final Payment, the APA shall automatically be deemed amended as follows;

	
(i)
	
by deleting clauses (b), (c), (d) and (e) of Sections 1.05 thereof in their entirety;

1

 

 CH\1964176.1

 

(ii)by replacing Section 7.07 in its entirety with the following 

“7.07[Reserved]”

(ii) by deleted the definition of “Deferred Payment Amount” in its entirety from Section 8.01 of the APA.  

4.Amendments to TLA.  Upon Buyer’s deliver of the Final Payment, Section 5(a) of the TLA shall automatically be deemed amended as follows:

“a.Subject to the Licensor’s termination rights set forth in Section 5(b), the term of this License shall be perpetual.” 

Governing Law

(a); Jurisdiction. Sections 9.09 – 9.11 of the APA are incorporated herein by reference and made a part hereof. 

6.Confirmation of the APA.  Except as expressly modified hereby, the APA and TLA shall remain in full force and effect and is hereby ratified and confirmed in all respects.

7.Amendments; Waiver; Entire Agreement.  This Amendment may be amended, supplemented or modified in whole or in part if, but only if, such amendment, supplement or modification is in writing and is signed by each party hereto.  Any provision of this Amendment may be waived if, but only if, such waiver is in writing and is signed by the party or parties against whom enforcement of any such waiver is sought and specific reference to this Amendment is made in such writing.  The waiver by any party of a breach of any provision of this Amendment shall not operate or be construed as a further or continuing waiver of such breach or as a waiver of any other or subsequent breach.  No failure on the part of any party to exercise, and no delay in exercising, any right, power or remedy hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of such right, power or remedy by such Party preclude any other or further exercise thereof or the exercise of any other right, power or remedy. This Amendment together with the APA and TLA is the entire agreement among the parties hereto with respect to the subject matter hereof. 

 

[Signature page follows.]

 

2

 

 CH\1964176.1

 

IN WITNESS WHEREOF this Amendment has been duly executed and delivered by each Party as of the date first above written.

	
 
	
BUYER:
	
Staffing 360 georgia, llc

 

 

By:
Name: Brendan Flood
Title:Chairman and Chief Executive Officer

 

	
 
	
SELLERS:
	
FIRSTPRO INC.

 

 

By:
Name:
Title:

 

 

FIRSTPRO GEORGIA, LLC

 

 

By:
Name:
Title:

 

PRINCIPAS: 

By:
Name:April F. Nagle

 

 

By:
Name:Philip A. Nagle

 

[Signature Page to Amendment Agreement]EX-10.21

 EXHIBIT 10.21 

AMENDMENT #1 TO RESEARCH AND DEVELOPMENT AGREEMENT 

This AMENDMENT #1 (“AMENDMENT #1”) to the RESEARCH AND DEVELOPMENT AGREEMENT (the “AGREEMENT”) is
effective upon execution of the NEW RESEARCH PROGRAM by and among THE UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER (“UTMDACC”), INTREXON CORPORATION (“INTREXON”) and ZIOPHARM ONCOLOGY, INC. (“ZIOPHARM”). Capitalized
terms used herein and not defined shall have the meaning ascribed to them in the AGREEMENT. 
 Whereas,
INTREXON, ZIOPHARM, and UTMDACC have a mutual interest in amending the AGREEMENT as follows with respect to INVENTIONS arising from the performance of certain NEW RESEARCH PROGRAMS: 

Notwithstanding Sections 6.1 and 6.3 of the AGREEMENT, for any NEW RESEARCH PROGRAM wholly funded by INTREXON and/or ZIOPHARM,
INTREXON shall solely own all INVENTIONS solely or jointly made by employees, other agents and consultants of UTMDACC that are conceived or reduced to practice in the performance of any of the attached Research Work Plan(s). All such INVENTIONS are
hereby assigned to INTREXON. For any NEW RESEARCH PROGRAM that is not wholly funded by INTREXON and/or ZIOPHARM, Sections 6.1 and 6.3 shall remain in effect with respect to such NEW RESEARCH PROGRAM. Each Research Work Plan will identify the
specific ownership rights of the parties in INVENTIONS as set forth in this AMENDMENT #1 
 All other terms and conditions
of the AGREEMENT remain in full force and effect. 
 IN WITNESS WHEREOF, the parties hereto have duly executed this AMENDMENT #1 to
the AGREEMENT by duly authorized representatives. 
  

											
	THE UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER

  

											
						
	By:	 	     /s/ Chris McKee
	 	        	  	Date:	  	    8/30/2016            	  	                                      
              

											
	Name:	 	Chris McKee, MHA	 	        	  		  		  	                                      
              

											
	Title:	 	Vice President, Business Operations	  		  	                                      
              
		
	INTREXON CORPORATION	  	                                      
              

  

											
						
	By:	 	     /s/ Jeffrey Perez
	 	        	  	Date:	  	    8/25/2016            	  	                                      
              

											
	Name:	 	Jeffrey Perez	 	        	  		  		  	                                      
              

											
	Title:	 	Senior Vice President	 	        	  		  		  	                                      
              

											
	ZIOPHARM ONCOLOGY, INC.	  	

  

											
						
	By:	 	     /s/ Caesar Belbel
	 	        	  	Date:	  	    8/29/2016            	  	                                      
              

											
	 Name:
	  	 Caesar Belbel
	  		  		  		  	

											
	 Title:
	  	 EVP, COO, Chief Legal OfficerEX-10.22

 EXHIBIT 10.22 

AMENDMENT #2 TO THE RESEARCH AND DEVELOPMENT AGREEMENT 

This AMENDMENT #2 (“AMENDMENT #2”) to the RESEARCH AND DEVELOPMENT AGREEMENT (the “AGREEMENT”) is entered
into as of January 17, 2017 by and among THE UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER (“UTMDACC”), INTREXON CORPORATION (“INTREXON”) and ZIOPHARM ONCOLOGY, INC. (“ZIOPHARM”). Capitalized terms used herein
and not defined shall have the meaning ascribed to them in the AGREEMENT. 
 Whereas, INTREXON, ZIOPHARM, and UTMDACC have a
mutual interest in amending the Agreement as follows with respect to payment for the funding of RESEARCH PROGRAMS. 
 Now,
therefore, in consideration of the mutual promises and covenants herein contained, the parties agree as follows. 

1.    From and after the effective date of this AMENDMENT #2, ZIOPHARM may set off against
the advance quarterly payments to MDACC required under Section 5.2(B) of the AGREEMENT those expenditures incurred and actually paid by ZIOPHARM during the prior three-month period for third party costs in support of the RESEARCH PROGRAMS that
were approved in advance by the JSC. In the event the total expenditures incurred and actually paid by ZIOPHARM exceed the amount approved by the JSC by greater than ten percent (10%), such overages may not be set off until further review and
approval by the JSC is completed. ZIOPHARM shall provide MDACC with all documentation substantiating all such expenditures as reasonably requested by MDACC. 

All other terms and conditions of the AGREEMENT remain in full force and effect. 

 IN WITNESS WHEREOF, the parties hereto have duly executed this AMENDMENT #2 to the
AGREEMENT by duly authorized representatives. 
  

									
	THE UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER

  

									
	 By:
	 	     /s/ Wesley Harrott
	  	       Date:
	  	
    1/19/2017            

	  	                                 
                   
	 Name:
	 	 Wesley Harrott
	  		  		  	
	 Title:
	 	 Associate VP, Research and Administration
	  	

  

									
	INTREXON CORPORATION	  	

  

									
	 By:
	 	     /s/ Jeffrey Perez
	  	       Date:
	  	
    1/18/2017            
	  	
	 Name:
	 	 Jeffrey Perez
	  		  		  	
	 Title:
	 	 Senior Vice President
	  		  		  	

  

									
	ZIOPHARM ONCOLOGY, INC.	  	

  

									
	 By:
	 	     /s/ Caesar Belbel
	  	       Date:
	  	
    1/18/2017            
	  	
	 Name:
	 	 Caesar Belbel
	  		  		  	
	 Title:
	 	 EVP, COO, Chief Legal Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00292-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00292-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00292-of-00352.parquet"}]]